- Home
- MAMO vs ATOS Comparison
MAMO vs ATOS Comparison
Compare MAMO & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMO
- ATOS
- Stock Information
- Founded
- MAMO 2008
- ATOS 2009
- Country
- MAMO United States
- ATOS United States
- Employees
- MAMO N/A
- ATOS N/A
- Industry
- MAMO
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- MAMO
- ATOS Health Care
- Exchange
- MAMO NYSE
- ATOS Nasdaq
- Market Cap
- MAMO 91.0M
- ATOS 107.2M
- IPO Year
- MAMO 2024
- ATOS 2012
- Fundamental
- Price
- MAMO $2.14
- ATOS $0.94
- Analyst Decision
- MAMO
- ATOS Strong Buy
- Analyst Count
- MAMO 0
- ATOS 3
- Target Price
- MAMO N/A
- ATOS $6.17
- AVG Volume (30 Days)
- MAMO 34.3K
- ATOS 1.5M
- Earning Date
- MAMO 08-11-2025
- ATOS 08-11-2025
- Dividend Yield
- MAMO N/A
- ATOS N/A
- EPS Growth
- MAMO N/A
- ATOS N/A
- EPS
- MAMO N/A
- ATOS N/A
- Revenue
- MAMO $95,959,187.00
- ATOS N/A
- Revenue This Year
- MAMO N/A
- ATOS N/A
- Revenue Next Year
- MAMO N/A
- ATOS N/A
- P/E Ratio
- MAMO N/A
- ATOS N/A
- Revenue Growth
- MAMO N/A
- ATOS N/A
- 52 Week Low
- MAMO $1.84
- ATOS $0.55
- 52 Week High
- MAMO $4.66
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- MAMO N/A
- ATOS 58.44
- Support Level
- MAMO N/A
- ATOS $0.81
- Resistance Level
- MAMO N/A
- ATOS $0.88
- Average True Range (ATR)
- MAMO 0.00
- ATOS 0.05
- MACD
- MAMO 0.00
- ATOS 0.01
- Stochastic Oscillator
- MAMO 0.00
- ATOS 84.07
About MAMO MASSIMO GROUP
Massimo Group is engaged in the mid-tier band the (Mid-Tier Band) of the Powersports Vehicles and Boats Industry. It manufacture, import and distribute a diversified portfolio of products divided into two main lines: a motor sports brand consisting of utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), motorcycles, scooters, golf carts, and a juvenile line from go karts to balance bikes; and a motor boat line consisting of pontoon and tritoon boats (Pontoon Boats).
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.